PMID- 18176846
OWN - NLM
STAT- MEDLINE
DCOM- 20081104
LR  - 20181113
IS  - 1080-0549 (Print)
IS  - 1080-0549 (Linking)
VI  - 35
IP  - 1-2
DP  - 2008 Oct
TI  - Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them?
PG  - 47-58
LID - 10.1007/s12016-007-8071-9 [doi]
AB  - Antineutrophil cytoplasmic antibodies (ANCA) are directed against enzymes found 
      in the granules of the polymorphonuclear (PMN) leukocytes. They are detected by 
      indirect immunofluorescence microscopy assays on human ethanol fixed neutrophils. 
      Three different fluorescence patterns can be distinguished: a cytoplasmic pattern 
      (cANCA), a perinuclear pattern (pANCA), and an atypical pattern (aANCA). The use 
      of other fixatives, e.g., formalin and methanol, allows differentiation between 
      the pANCA and the antinuclear antibodies. ANCA specificity is determined by solid 
      phase assays (ELISA, immunodot, and multiplex assay). ANCA with high titres and 
      defined specificities (antiproteinase 3 [PR 3] or antimyeloperoxidase [MPO]) are 
      proven to be good serological markers of active primary systemic vasculitis: c/PR 
      3-ANCA for Wegener's granulomatosis and p/MPO-ANCA for microscopic polyangiitis. 
      The former have higher sensitivity and specificity for Wegener's granulomatosis 
      than the latter for microscopic polyangiitis. ANCA with low titres and unknown 
      specificity have been detected in a wide range of inflammatory and infectious 
      diseases leading to a critical reappraisal of the diagnostic significance of ANCA 
      testing. Physicians must keep in mind the possible occurrence of infectious 
      diseases like subacute endocarditis that could be dramatically worsened by 
      irrelevant immunosuppressive therapy. ANCA findings in certain manifestations, 
      such as the pulmonary-renal syndrome in which massive pulmonary hemorrhage can 
      quickly be life-threatening, warrant ANCA testing as an emergency test for 
      patient care.
FAU - Beauvillain, C
AU  - Beauvillain C
AD  - Universite d'Angers, IFR132, Inserm U564, Angers, France.
FAU - Delneste, Y
AU  - Delneste Y
FAU - Renier, G
AU  - Renier G
FAU - Jeannin, P
AU  - Jeannin P
FAU - Subra, J F
AU  - Subra JF
FAU - Chevailler, A
AU  - Chevailler A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Antimicrobial Cationic Peptides)
RN  - 0 (Blood Proteins)
RN  - 0 (bactericidal permeability increasing protein)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EC 3.4.21.76 (Myeloblastin)
SB  - IM
MH  - Antibodies, Antineutrophil Cytoplasmic/*analysis
MH  - Antimicrobial Cationic Peptides/immunology
MH  - Blood Proteins/immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Fluorescent Antibody Technique, Indirect
MH  - Humans
MH  - Immunoblotting
MH  - Myeloblastin/immunology
MH  - Neutrophils/immunology
MH  - Peroxidase/immunology
RF  - 79
EDAT- 2008/01/08 09:00
MHDA- 2008/11/05 09:00
CRDT- 2008/01/08 09:00
PHST- 2008/01/08 09:00 [pubmed]
PHST- 2008/11/05 09:00 [medline]
PHST- 2008/01/08 09:00 [entrez]
AID - 10.1007/s12016-007-8071-9 [doi]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2008 Oct;35(1-2):47-58. doi: 10.1007/s12016-007-8071-9.